A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican social security program

Cancer Causes and Control

Volumn 21, Issue 10, 2010, Pages 1693-1700

  Lazcano Ponce, Eduardo ^a   Lörincz, Attila T ^b   Salmerón, Jorge ^a,c   Fernández, Irma ^c   Cruz, Aurelio ^a   Hernández, Pilar ^a   Mejia, Ivonne ^c   Hernández Ávila, Mauricio ^d  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^d Secretariat of Health   (Mexico)

Author keywords

Cancer; Cervical cytology; HPV testing; Mexico

Indexed keywords

VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER SCREENING; COLPOSCOPY; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC ACCURACY; FEASIBILITY STUDY; FEMALE; GEOGRAPHIC DISTRIBUTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PILOT STUDY; PREVALENCE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SOCIAL SECURITY; UTERINE CERVIX CANCER; VIRUS DETECTION; WART VIRUS;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; CYTODIAGNOSIS; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; MEXICO; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SOCIAL SECURITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 77956978527     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-010-9598-2     Document Type: Article

References (42)

1. G Ogedegbe AN Cassells CM Robinson K DuHamel JN Tobin CH Sox AJ Dietrich 2005 Perceptions of barriers and facilitators of cancer early detection among low-income minority women in community health centers J Natl Med Assoc 97 2 162 170 15712779
2. E Lazcano-Ponce P Alonso JA Ruiz-Moreno M Hernández-Avila 2003 Recommendations for cervical cancer screening programs in developing countries. The need for equity and technological development Salud Publica Mex 45 Suppl 3 S449 S462 14746039
3. EC Lazcano-Ponce R Castro B Allen P Nájera PA Alonso de Ruíz M Hernández-Avila 1999 Barriers to early detection of cervical-uterine cancer in Mexico J Womens Health 8 3 399 408 1:STN:280:DyaK1M3ls12htA%3D%3D 10.1089/jwh.1999.8.399 10326994
4. Chu KC, Miller BA, Springfield SA (2007) Measures of racial/ethnic health disparities in cancer mortality rates and the influence of socioeconomic status. J Natl Med Assoc 99(10):1092-1100 (1102-1104)
5. SS Raab BA Jones R Souers JA Tworek 2008 The effect of continuous monitoring of cytologic-histologic correlation data on cervical cancer screening performance Arch Pathol Lab Med 132 1 16 22 18181668
6. JA Tworek BA Jones S Raab KM Clary MK Walsh 2007 The value of monitoring human papillomavirus DNA results for Papanicolaou tests diagnosed as atypical squamous cells of undetermined significance: a College of American Pathologists Q-Probes study of 68 institutions Arch Pathol Lab Med 131 10 1525 1531 17922588
7. DeMay RM (1996) Cytopathology of false negatives preceding cervical carcinoma. Am J Obstet Gynecol 175(4 Pt 2):1110-1113
8. K Behbakht A Lynch S Teal K Degeest S Massad 2004 Social and cultural barriers to Papanicolaou test screening in an urban population Obstet Gynecol 104 6 1355 1361 15572502
9. Branca M, Ciotti M, Giorgi C, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Syrjänen S, Favalli C, Syrjänen K, on behalf of the HPV-Pathogen ISS Study Group (2008) Predicting high-risk human papillomavirus infection, progression of cervical intraepithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling. Int J Gynecol Pathol
10. Baseman JG, Kulasingam SL, Harris TG, Hughes JP, Kiviat NB, Mao C, Koutsky LA (2008) Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States. Am J Obstet Gynecol
11. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N, New Technologies for Cervical Cancer Screening Working Group (2008) Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 100(7):492-501
12. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J (2009) Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 101(2):88-99
13. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL, Canadian Cervical Cancer Screening Trial Study Group (2007) Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357(16):1579-1588
14. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, Snijders PJ, Meijer CJ (2007) Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370(9601):1764-1772
15. Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M (2005) Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer 93(8):862-867
16. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, Gilham C, Baysson H, Roberts C, Dowie R, Desai M, Mather J, Bailey A, Turner A, Moss S, Peto J (2009) HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 10(7):672-682
17. Cuzick J, Szarewski A, Mesher D, Cadman L, Austin J, Perryman K, Ho L, Terry G, Sasieni P, Dina R, Soutter WP (2008) Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-results from the Hammersmith study. Int J Cancer
18. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA (2002) Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 288(14):1749-1757
19. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A (2009) Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 101(23):1612-1623
20. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D, 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference (2007) 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 197(4):346-355
21. Bistoletti P, Sennfält K, Dillner J (2008) Cost-effectiveness of primary cytology and HPV DNA cervical screening. Int J Cancer 122(2):372-376
22. JD Goldhaber-Fiebert NK Stout JA Salomon KM Kuntz SJ Goldie 2008 Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16, 18 vaccination J Natl Cancer Inst 100 5 308 320 10.1093/jnci/djn019 18314477
23. CM Wheeler 2007 Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing Nat Clin Pract Oncol 4 4 224 235 10.1038/ncponc0770 17392713
24. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DA, Snijders PJ (2008) Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124(3):516-520
25. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T, Joint European Cohort Study (2008) Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337:a1754
26. Jhala D, Eltoum I (2007) Barriers to adoption of recent technology in cervical screening. Cytojournal 4:16
27. (2008) Is HPV testing better than a pap test? Not just yet. Mayo Clin Womens Healthsource 12(4):3
28. LP Howell H Zhou W Wu R Davis 2004 Significance of subclassifying high-grade squamous intraepithelial lesions into moderate dysplasia/CIN II versus severe dysplasia/CIN III/CIS in the Bethesda System terminology Diagn Cytopathol 30 5 362 366 10.1002/dc.20018 15108239
29. AT Lörincz 1996 Hybrid Capture method for detection of human papillomavirus DNA in clinical specimens: a tool for clinical management of equivocal Pap smears and for population screening J Obstet Gynaecol Res 22 6 629 636 9037955
30. T Fagan 1999 Exact 95% confidence intervals for differences in binomial proportions Comput Biol Med 29 83 87 1:STN:280:DyaK1M3isVSlsQ%3D%3D 10.1016/S0010-4825(98)00047-X 10207656
31. Ronco G, Cuzick J, Segnan N, Brezzi S, Carozzi F, Folicaldi S, Dalla Palma P, Del Mistro A, Gillio-Tos A, Giubilato P, Naldoni C, Polla E, Iossa A, Zorzi M, Confortini M, Giorgi-Rossi P, NTCC working group (2007) HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer 43(3):476-480
32. Sheriff SK, Petry KU, Ikenberg H, Crouse G, Mazonson PD, Santas CC (2007) An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany. Eur J Health Econ
33. M Reid-Nicholson RM Gatscha ER Riedel O Lin 2007 Atypical squamous cells, cannot exclude high grade intraepithelial lesion (ASC-H): does HPV matter? Diagn Cytopathol 35 1 1 5 10.1002/dc.20576 17173297
34. SS Raab BA Jones R Souers JA Tworek 2008 The effect of continuous monitoring of cytologic-histologic correlation data on cervical cancer screening performance Arch Pathol Lab Med 132 1 16 22 18181668
35. E Lazcano-Ponce LS Palacio-Mejia B Allen-Leigh E Yunes-Diaz P Alonso R Schiavon M Hernandez-Avila 2008 Decreasing cervical cancer mortality in Mexico: effect of Papanicolaou coverage, birthrate, and the importance of diagnostic validity of cytology Cancer Epidemiol Biomarkers Prev 17 10 2808 2817 10.1158/1055-9965.EPI-07-2659 18843027
36. Eltoum IA, Roberson J (2007) Impact of HPV testing, HPV vaccine development, and changing screening frequency on national Pap test volume: projections from the National Health Interview Survey (NHIS). Cancer 111(1):34-40
37. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahé C, Wright TC, Alliance for Cervical Cancer Prevention Cost Working Group (2005) Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 353(20):2158-2168
38. Goldie SJ, Kim JJ, Myers E (2006) Chapter 19: cost-effectiveness of cervical cancer screening. Vaccine 24(Suppl 3):S164-S170
39. KJ Kimball WK Huh 2008 Cytology versus high-risk HPV testing for follow-up of HPV-positive women without CIN J Natl Compr Canc Netw 6 1 96 100 18267062
40. S Syrjänen IP Shabalova N Petrovichev VP Kozachenko T Zakharova J Pajanidi JI Podistov G Chemeris LG Sozaeva EV Lipova I Tsidaeva OG Ivanchenko AA Pshepurko S Zakharenko R Nerovjna LB Kljukina OA Erokhina MF Branovskaja M Nikitina V Grunberga A Grunberg A Juschenko P Tosi M Cintorino R Santopietro KJ Syrjänen 2002 Human papillomavirus testing and conventional Pap smear cytology as optional screening tools of women at different risks for cervical cancer in the countries of the former Soviet Union J Low Genit Tract Dis 6 2 97 110 10.1097/00128360-200204000-00006 17051008
41. Longatto-Filho A, Erzen M, Branca M, Roteli-Martins C, Naud P, Derchain SF, Hammes L, Sarian LO, Bragança JF, Matos J, Gontijo R, Lima T, Maeda MY, Tatti S, Syrjänen S, Dores G, Lörincz A, Syrjänen K (2006) Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: experience from the Latin American Screening study. Int J Gynecol Cancer 16(3):955-962
42. Franco EL, Cuzick J, Hildesheim A, de Sanjosé S (2006) Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24(Suppl 3):S171-S177